deltatrials
Completed PHASE4 INTERVENTIONAL 4-arm NCT00705341

MethaCholine Bronchoprovocation Study (MeCIS) (MeCIS)

MethaCholine Bronchoprovocation - Influence of High Potency Inhaled corticoSteroids in Asthma (MeCIS) Study

Sponsor: Baylor College of Medicine

Conditions Asthma
Interventions fluticasone
Updated 9 times since 2017 Last updated: Feb 11, 2013 Started: Jan 31, 2009 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00705341, this PHASE4 trial focuses on Asthma and remains completed. Sponsored by Baylor College of Medicine, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

The study consists of two phases. The first phase is a cross-sectional, case-control study measuring the sensitivity and specificity of methacholine challenge testing for differentiating asthmatic participants from non-asthmatic controls. The second phase is a cross-over, randomized, double-masked trial designed to evaluate the impact of high dose versus low dose inhaled corticosteroids (ICS) on bronchial hyperreactivity (BHR) in asthmatics.

The study consists of two phases. The first phase is a cross-sectional, case-control study measuring the sensitivity and specificity of methacholine challenge testing for differentiating asthmatic participants from non-asthmatic controls. The second phase is a cross-over, randomized, double-masked trial designed to evaluate the impact of high dose versus low dose inhaled corticosteroids (ICS) on bronchial hyperreactivity (BHR) in asthmatics.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshotCompleted~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 7 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed PHASE4

  2. Sep 2025 — Present [monthly]

    Completed PHASE4

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

Show 4 earlier versions
  1. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE4

  2. Jun 2018 — Jun 2019 [monthly]

    Completed PHASE4

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baylor College of Medicine
  • Duke University
  • Indiana University
  • Johns Hopkins Bloomberg School of Public Health
  • Long Island Jewish Medical Center
  • Louisiana State University Health Sciences Center in New Orleans
  • NYU Langone Health
  • National Jewish Health
  • Nemours Children's Clinic
  • North Shore University Hospital
  • Northwestern University
  • Ohio State University
  • St. Louis University
  • University of California, San Diego
  • University of Florida
  • University of Miami
  • University of Missouri-Columbia
  • University of South Florida
  • University of Vermont
  • Washington University School of Medicine
Data source: Johns Hopkins Bloomberg School of Public Health

For direct contact, visit the study record on ClinicalTrials.gov .